New River kept by Merrill at buy

Merrill Lynch analyst David Munno reiterated New River Pharmaceuticals Inc. at a buy rating. The Shire/Impax settlement on Adderall XR clears the way somewhat for the initial launch of NRP104. The agreement may push generic Adderall XR launches to as late as 2010, later than Merrill's expectation of late '07 or early '08 and should facilitate transition to NRP104. Shares of the Radford, Va., pharmaceutical company were up 69 cents, or 2.11%, at $33.40 on volume of 543,594 shares versus the three-month running average of 237,803 shares. (Nasdaq: NRPH)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.